The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns
- PMID: 38743292
- DOI: 10.1007/s00204-024-03765-8
The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns
Abstract
The phenylethylamine, 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'), is the prototypical example of an entactogen. Its original placement in highly restrictive drug usage categories in the US and UK, led to an inevitable restriction on MDMA neuroscience research and treatment. The dominant pharmacological effects of MDMA are its properties of release and inhibition of reuptake of amine neurotransmitter transporters for dopamine, norepinephrine, and serotonin. MDMA is an agonist of a wide range of receptors; its mood-altering effects are mediated via 5-HT2A receptors; this receptor may also mediate its effects on body temperature, analgesia, and anxiolytic properties. The mechanisms underlying MDMA's entactogenic properties of sociability and interpersonal closeness are not known but release and involvement of oxytocin, a peptide thought by some to be involved in social bonding, has been suggested. Adverse effects of MDMA are mostly transient; acute multiorgan adverse effects occurring during raves or crowded dance gatherings include dehydration, hyperthermia, seizures, rhabdomyolysis, disseminated intravascular coagulation, and acute renal failure. Deaths following MDMA taken by itself are rare compared to fatalities following coadministration with other drugs. A recent FDA-approved phase 3 clinical trial of MDMA for post-traumatic stress disorder (PTSD) led to the conclusion that MDMA-assisted therapy represents a potential breakthrough treatment meriting expedited clinical evaluation. Despite the ongoing deliberations by the FDA and EMA for approval of MDMA treatment of PTSD, the Australian Therapeutic Goods Administration (TGA) recently announced that after an evaluation of the therapeutic value, benefits, and risks of MDMA, it will permit its prescribing for the treatment of PTSD. Further examples of regulatory relaxation toward MDMA-assisted psychotherapy are underway. These include the FDA's recently approved clinical trial to assess MDMA's efficacy in the treatment of "asociality" in patients with schizophrenia and an open trial of MDMA treatment for alcohol-use disorder which showed decreased alcohol consumption. There are also ongoing studies on the little understood startle response, anxiety associated with life-threatening illness, and social anxiety in autistic adults.
Keywords: 3,4-Methylenedioxymethamphetamine; Ecstasy (MDMA); MDMA; MDMA and PTSD; MDMA and coadministration with other drugs; MDMA deaths; MDMA-assisted psychotherapy; Toxicity of MDMA.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA).Psychopharmacology (Berl). 2017 Oct;234(19):2883-2895. doi: 10.1007/s00213-017-4684-8. Epub 2017 Jul 24. Psychopharmacology (Berl). 2017. PMID: 28741031 Free PMC article.
-
Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy.J Psychopharmacol. 2021 May;35(5):512-536. doi: 10.1177/0269881120920420. Epub 2020 Sep 10. J Psychopharmacol. 2021. PMID: 32909493 Free PMC article. Review.
-
3,4-methylenedioxymethamphetamine (MDMA): current perspectives.Subst Abuse Rehabil. 2013 Nov 21;4:83-99. doi: 10.2147/SAR.S37258. eCollection 2013. Subst Abuse Rehabil. 2013. PMID: 24648791 Free PMC article. Review.
-
MDMA-Based Psychotherapy in Treatment-Resistant Post-Traumatic Stress Disorder (PTSD): A Brief Narrative Overview of Current Evidence.Diseases. 2023 Nov 3;11(4):159. doi: 10.3390/diseases11040159. Diseases. 2023. PMID: 37987270 Free PMC article. Review.
-
Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist's Perspective.Neurotherapeutics. 2017 Jul;14(3):741-749. doi: 10.1007/s13311-017-0531-1. Neurotherapeutics. 2017. PMID: 28477247 Free PMC article. Review.
References
-
- ACMD (Advisory Council on the Misuse of Drugs). MDMA (‘ecstasy’): A review of its harms and classification under the Misuse of Drugs Act 1971 (Nutt DJ, 2008) https://assets.publishing.service.gov.uk/media/5a7ad072e5274a34770e74e6/... (Accessed Oct 20, 2023)
-
- Ajaelo I, Koenig K, Snoey E (1998) Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use. Acad Emerg Med 5(8):839–840. https://doi.org/10.1111/j.1553-2712.1998.tb02512.x - DOI - PubMed
-
- Assi S, Gulyamova N, Ibrahim K, Kneller P, Osselton D (2017) Profile, effects, and toxicity of novel psychoactive substances: a systematic review of quantitative studies. Hum Psychopharmacol. https://doi.org/10.1002/hup.2607 - DOI - PubMed
-
- Baldo BA (2018) Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch Toxicol 92:2457–2473. https://doi.org/10.1007/s00204-018-2244-6 - DOI - PubMed
-
- Baldo BA (2023) Allergic and other adverse reactions to drugs used in anesthesia and surgery. Anaesthesiol Perioper Sci 1:16. https://doi.org/10.1007/s44254-023-00018-2 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous